Patients with advanced kidney cancer, who received a targeted drug combined with a checkpoint-blocker immunotherapy agent had longer survival than patients treated with the standard targeted drug, said an investigator from ...
Feb 13, 2021
0
5
A nationwide panel of experts has developed the first mammography guidelines for older survivors of breast cancer, providing a framework for discussions between survivors and their physicians on the pros and cons of screening ...
Jan 28, 2021
0
10
Four years after patients with melanoma were treated with a personalized cancer vaccine, the immune response kindled by the vaccine remains robust and effective in keeping cancer cells under control, researchers at Dana-Farber ...
Jan 21, 2021
0
353
In one of the first studies to examine the impact of the COVID-19 pandemic on cancer diagnoses, researchers at Dana-Farber/Brigham and Women's Cancer Center document a substantial decline in cancer and precancer diagnoses ...
Jan 14, 2021
0
2
Scientists at Dana-Farber Cancer Institute and the Centers for Disease Control and Prevention have uncovered new evidence of the potential health risks of chemicals in tobacco and marijuana smoke.
Jan 11, 2021
2
216
Scientists at Dana-Farber Cancer Institute and Mass General Cancer Center have created molecular ON-OFF switches to regulate the activity of CAR T cells, a potent form of cell-based immunotherapy that has had dramatic success ...
Jan 6, 2021
0
48
Adding an immune checkpoint inhibitor to the standard chemotherapy regimen for patients with early-stage breast cancer places no greater burden on patients' ability to perform day-to-day activities than chemotherapy alone, ...
Dec 10, 2020
0
1
Many patients with diffuse large B-cell lymphoma (DLBCL) can be cured by a transplant using their own blood-forming stem cells, but as many as half eventually relapse. New research led by Dana-Farber Cancer Institute scientists ...
Dec 7, 2020
0
2
The novel oral drug venetoclax can be safely added to standard therapies for some high-risk myeloid blood cancers and in early studies the combination shows promise of improved outcomes, say scientists from Dana-Farber Cancer ...
Dec 6, 2020
0
5
A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a phase 2 clinical trial, Dana-Farber Cancer ...
Dec 5, 2020
0
187
